Surgery for pancreatic cancer: current controversies and challenges

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL, Miller KD, Ahmedin J. Cancer statistics. CA Cancer J. Clin. 70, 7–30 (2020).
  MedlineGoogle Scholar
• 2. Kleeff J, Korc M, Apte M et al. Pancreatic cancer. Nat. Rev. Dis. Primers. 2(1), 1–22 (2016).
  Google Scholar
• 3. Howard TJ, Krug JE, Yu J et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J. Gastrointest. Surg. 10(10), 1338–1346 (2006).
  MedlineGoogle Scholar
• 4. Ghaneh P, Kleeff J, Halloran CM et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann. Surg. 269(3), 520–529 (2019).
  MedlineGoogle Scholar
• 5. Strobel O, Hank T, Hinz U et al. Pancreatic cancer surgery. Ann. Surg. 265(3), 565–573 (2017).
  MedlineGoogle Scholar
• 6. Hank T, Hinz U, Tarantino I et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br. J. Surg. 105(9), 1171–1181 (2018).
  Medline CASGoogle Scholar
• 7. Neoptolemos JP, Palmer DH, Ghaneh P et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomised, phase 3 trial. Lancet 389(10073), 1011–1024 (2017). •• Multicenter, randomized control trial with reasonable large sample size. It showed that R0 resection conferred significant benefit in overall survival, despite use of combination chemotherapy, which underlines the importance of margin-negative resection.
  Medline CASGoogle Scholar
• 8. Windsor JA, Barreto SG. The concept of ‘borderline resectable’ pancreatic cancer: limited foundations and limited future? J. Gastrointest. Oncol. 8(1), 189–193 (2017).
  MedlineGoogle Scholar
• 9. Merkow RP, Bilimoria KY, Tomlinson JS et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann. Surg. 260(2), 372–377 (2014).
  MedlineGoogle Scholar
• 10. Hackert T, Sachsenmaier M, Hinz U et al. Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients. Ann. Surg. 264(3), 457–463 (2016).
  MedlineGoogle Scholar
• 11. Blazer M, Wu C, Goldberg RM, Phillips G et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann. Surg. Oncol. 22(4), 1153–1159 (2015).
  MedlineGoogle Scholar
• 12. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817–1825 (2011).
  Medline CASGoogle Scholar
• 13. Barenboim A, Lahat G, Geva R et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur. J. Surg. Oncol. 44(10), 1619–1623 (2018).
  MedlineGoogle Scholar
• 14. Byun Y, Han Y, Kang JS et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J. Hepatobiliary. Pancreat. Sci. 26(9), 416–425 (2019).
  MedlineGoogle Scholar
• 15. Petrelli F, Coinu A, Borgonovo K et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 44(4), 515–521 (2015).
  Medline CASGoogle Scholar
• 16. Yoo C, Kang J, Kim KP et al. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget 8(28), 46337–46347 (2017).
  MedlineGoogle Scholar
• 17. Ghaneh PD, Palmer DH, Cicconi S et al. ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J. Clin. Oncol. 38(Suppl. 15), 4505 (2020).
  Google Scholar
• 18. Macedo FI, Ryon E, Maithel SK et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann. Surg. 270(3), 400–413 (2019).
  MedlineGoogle Scholar
• 19. Neoptolemos JP, Stocken DD, Dunn JA et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg. 234(6), 758–768 (2001).
  Medline CASGoogle Scholar
• 20. Rangelova E, Wefer A, Persson S et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann. Surg. 273(3), 579–586 (2021).
  MedlineGoogle Scholar
• 21. Tinchon C, Hubmann E, Pichler A et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta. Oncologica. 52(6), 1231–1233 (2013).
  Medline CASGoogle Scholar
• 22. Nitsche U, Wenzel P, Siveke JT et al. Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: a single-center experience. Ann. Surg. Oncol. 22(3), 1212–1220 (2015).
  Google Scholar
• 23. Moningi S, Dholakia AS, Raman SP et al. The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann. Surg. Oncol. 22(7), 2352–2358 (2015).
  MedlineGoogle Scholar
• 24. Patel M, Hoffe S, Malafa M et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J. Surg. Oncol. 104(2), 155–161 (2011).
  MedlineGoogle Scholar
• 25. Versteijne E, Suker M, Groothuis K et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J. Clin. Oncol. 38(16), 1763–1773 (2020). •• Multicenter, randomized control trial which showed that addition of radiation to neoadjuvant chemotherapy led to significant increase in R0 resection and disease-free-survival, though overall survival was not different.
  Medline CASGoogle Scholar
• 26. Oettle H, Neuhaus P, Hochhaus A et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 310(14), 1473–1481 (2013).
  Medline CASGoogle Scholar
• 27. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 304(10), 1073–1081 (2010).
  Medline CASGoogle Scholar
• 28. Lim KH, Chung E, Khan A et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist 17(2), 192–200 (2012).
  Medline CASGoogle Scholar
• 29. Versteijne E, Suker M, Punt CJA et al. Preoperative chemoradiotherapy potentially improves outcome for (borderline) resectable pancreatic cancer: preliminary results of the Dutch randomized phase III PREOPANC trial. Int. J. Radiat. Oncol. Biol. Phys. 102(5), 1606–1607 (2018).
  Google Scholar
• 30. Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert. Opin. Investig. Drugs 18(3), 335–348 (2009).
  Medline CASGoogle Scholar
• 31. Motoi F, Kosuge T, Ueno H et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn. J. Clin. Oncol. 49(2), 190–194 (2019).
  MedlineGoogle Scholar
• 32. Mokdad AA, Minter RM, Zhu H et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J. Clin Oncol. 35(5), 515–522 (2017).
  MedlineGoogle Scholar
• 33. Lee YS, Lee JC, Yang SY et al. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: a systematic review and meta-analysis. Sci. Reports 9(1), 1–8 (2019).
  MedlineGoogle Scholar
• 34. National Comprehensive Cancer Network. NCCN guidelines version 1. 2020. Pancreatic adenocarcinoma.
  Google Scholar
• 35. He J, Blair AB, Groot VP et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann. Surg. 268(1), 1–8 (2018).
  MedlineGoogle Scholar
• 36. Barreto SG, Loveday B, Windsor JA et al. Detecting tumor response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J. Surg. 89(5), 481–487 (2019). •• Explores the accuracy of imaging modalities to predict resectability in borderline resectable pancreatic cancer/locally advanced pancreatic cancer.
  MedlineGoogle Scholar
• 37. Hozaeel W, Pauligk C, Homann N et al. Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. J. Clin Oncol. 33(Suppl. 15), TPS4152–TPS4152 (2015).
  Google Scholar
• 38. Labori KJ, Lassen K, Hoem D et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial-1 (NorPACT-1))–study protocol for a national multicenter randomized controlled trial. BMC Surg. 17(1), 1–7 (2017).
  MedlineGoogle Scholar
• 39. Heinrich S, Pestalozzi B, Lesurtel M et al. Adjuvant gemcitabine versus Neoadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 11(1), 1–7 (2011).
  MedlineGoogle Scholar
• 40. Okabayashi T, Shima Y, Iwata J et al. Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion. Langenbeck's Arch. Surg. 400(4), 487–494 (2015).
  MedlineGoogle Scholar
• 41. Ramacciato G, Nigri G, Petrucciani N et al. Pancreatectomy with mesenteric and portal vein resection for borderline resectable pancreatic cancer: multicenter study of 406 patients. Ann. Surg. Oncol. 23(6), 2028–2037 (2016).
  MedlineGoogle Scholar
• 42. Rosso E, Langella S, Addeo P et al. A safe technique for radical antegrade modular pancreatosplenectomy with venous resection for pancreatic cancer. J. Am Coll. Surg. 217(5), e35–e39 (2013).
  MedlineGoogle Scholar
• 43. Delpero JR, Boher JM, Sauvanet A et al. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie. Ann. Surg. Oncol. 22(6), 1874–1883 (2015).
  MedlineGoogle Scholar
• 44. Ishikawa OS, Ohigashi HI, Imaoka SH et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann. Surg. 215(3), 231–236 (1992).
  Medline CASGoogle Scholar
• 45. Nakao A, Kanzaki A, Fujii T et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann. Surg. 255(1), 103–108 (2012).
  MedlineGoogle Scholar
• 46. Kim PT, Wei AC, Atenafu EG et al. Planned versus unplanned portal vein resections during pancreaticoduodenectomy for adenocarcinoma. Br. J. Surg. 100(10), 1349–1356 (2013).
  Medline CASGoogle Scholar
• 47. Barreto SG, Windsor JA. Justifying vein resection with pancreatoduodenectomy. The Lancet Oncol. 17(3), e118–e224 (2016).
  MedlineGoogle Scholar
• 48. Bockhorn M, Uzunoglu FG, Adham M et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155(6), 977–988 (2014).
  MedlineGoogle Scholar
• 49. Sasson AR, Hoffman JP, Ross EA et al. En-bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J. Gastrointest. Surg. 6(2), 147–158 (2002).
  MedlineGoogle Scholar
• 50. Shoup M, Conlon KC, Klimstra D et al. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J. Gastrointest. Surg. 7(8), 946–952 (2003).
  MedlineGoogle Scholar
• 51. Kulkarni RV, Patil V, Bhandare MS et al. Vein resection without reconstruction (VROR) in pancreatoduodenectomy: expanding the surgical spectrum for locally advanced pancreatic tumors. Langenbeck's Arch. Surg. 405(7), 929–937 (2020).
  MedlineGoogle Scholar
• 52. Amico EC, Alves JR, João SA et al. Venous occlusion test applied to the tributaries of the superior mesenteric veins of the pancreas head infiltrated by tumor. J. Surg. Case. Rep. 2017(6), rjx109 (2017).
  MedlineGoogle Scholar
• 53. Rosado ID, Bhalla S, Sanchez LA et al. Pattern of venous collateral development after splenic vein occlusion in an extended Whipple procedure (Whipple at the splenic artery) and long-term results. J. Gastrointest. Surg. 21(3), 516–526 (2017).
  MedlineGoogle Scholar
• 54. Ono Y, Matsueda K, Koga R et al. Sinistral portal hypertension after pancreaticoduodenectomy with splenic vein ligation. Br. J. Surg. 102(3), 219–228 (2015).
  Medline CASGoogle Scholar
• 55. Tanaka H, Nakao A, Oshima K et al. Splenic vein reconstruction is unnecessary in pancreatoduodenectomy combined with resection of the superior mesenteric vein–portal vein confluence according to short-term outcomes. HPB (Oxford) 19(9), 785–792 (2017).
  MedlineGoogle Scholar
• 56. Tanaka M, Ito H, Ono Y et al. Impact of portal vein resection with splenic vein reconstruction after pancreatoduodenectomy on sinistral portal hypertension: who needs reconstruction? Surgery 165(2), 291–297 (2019).
  MedlineGoogle Scholar
• 57. Ferreira N, Oussoultzoglou E, Fuchshuber P et al. Splenic vein–inferior mesenteric vein anastomosis to lessen left-sided portal hypertension after pancreaticoduodenectomy with concomitant vascular resection. Arch. Surg. 146(12), 1375–1381 (2011).
  MedlineGoogle Scholar
• 58. Katz MH, Lee JE, Pisters PW et al. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J. Am. Coll. Surg. 215(2), e11–e18 (2012).
  MedlineGoogle Scholar
• 59. Christians KK, Riggle K, Keim R et al. Distal splenorenal and temporary mesocaval shunting at the time of pancreatectomy for cancer: initial experience from the Medical College of Wisconsin. Surgery 154(1), 123–131 (2013).
  MedlineGoogle Scholar
• 60. Ouaissi M, Hubert C, Verhelst R et al. Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure. World J. Surg. 34(11), 2648–2861 (2010).
  MedlineGoogle Scholar
• 61. Banz VM, Croagh D, Coldham C et al. Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas. Eur. J. Surg. Oncol. 38(1), 72–79 (2012).
  Medline CASGoogle Scholar
• 62. Murakami Y, Uemura K, Sudo T et al. Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. J. Surg. Oncol. 107(4), 414–421 (2013).
  MedlineGoogle Scholar
• 63. Ravikumar R, Sabin C, Hilal MA et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J. Am. Coll. Surg. 218(3), 401–411 (2014).
  MedlineGoogle Scholar
• 64. Wang F, Gill AJ, Neale M et al. Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 21(6), 1937–1947 (2014).
  Medline CASGoogle Scholar
• 65. Kulemann B, Hoeppner J, Wittel U et al. Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer. J. Gastrointest. Surg. 19(3), 438–444 (2015).
  MedlineGoogle Scholar
• 66. Wang WL, Ye S, Yan S et al. Pancreaticoduodenectomy with portal vein/superior mesenteric vein resection for patients with pancreatic cancer with venous invasion. Hepatobiliary Pancreat. Dis. Int. 14(4), 429–435 (2015).
  MedlineGoogle Scholar
• 67. Roch AM, House MG, Cioffi J et al. Significance of portal vein invasion and extent of invasion in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. J. Gastrointest. Surg. 20(3), 479–487 (2016).
  MedlineGoogle Scholar
• 68. Zhao X, Li LX, Fan H et al. Segmental portal/superior mesenteric vein resection and reconstruction with the iliac vein after pancreatoduodenectomy. J. Int. Med. Res. 44(6), 1339–1348 (2016).
  MedlineGoogle Scholar
• 69. Addeo P, Velten M, Averous G et al. Prognostic value of venous invasion in resected T3 pancreatic adenocarcinoma: depth of invasion matters. Surgery 162(2), 264–274 (2017).
  MedlineGoogle Scholar
• 70. Martin D, Petermann D, Fontanella S et al. Pancreatic adenocarcinoma with histologically proven portal vein infiltration: what is the outcome? Eur. J. Gastroenterol. Hepatol. 30(12), 1507–1513 (2018).
  MedlineGoogle Scholar
• 71. Xie ZB, Li J, Gu JC et al. Pancreatoduodenectomy with portal vein resection favors the survival time of patients with pancreatic ductal adenocarcinoma: a propensity score matching analysis. Oncol. Lett. 18(5), 4563–4572 (2019).
  Medline CASGoogle Scholar
• 72. Michalski CW, Kong B, Jäger C et al. Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. BMC Surg. 15(1), 1–8 (2015).
  MedlineGoogle Scholar
• 73. Mierke F, Hempel S, Distler M et al. Impact of portal vein involvement from pancreatic cancer on metastatic pattern after surgical resection. Ann. Surg. Oncol. 23(5), 730–736 (2016).
  MedlineGoogle Scholar
• 74. Snyder RA, Prakash LR, Nogueras-Gonzalez GM et al. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: patency rates and outcomes associated with thrombosis. J. Surg. Oncol. 117(8), 1648–1654 (2018).
  MedlineGoogle Scholar
• 75. Dua MM, Tran TB, Klausner J et al. Pancreatectomy with vein reconstruction: technique matters. HPB (Oxford) 17(9), 824–831 (2015).
  MedlineGoogle Scholar
• 76. Ravikumar R, Sabin C, Abu Hilal M et al. Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. Br. J. Surg. 104(11), 1539–1548 (2017).
  Medline CASGoogle Scholar
• 77. Fujii T, Nakao A, Yamada S et al. Vein resections >3 cm during pancreatectomy are associated with poor 1-year patency rates. Surgery 157(4), 708–715 (2015).
  MedlineGoogle Scholar
• 78. Glebova NO, Hicks CW, Piazza KM et al. Technical risk factors for portal vein reconstruction thrombosis in pancreatic resection. J. Vasc. Surg. 62(2), 424–433 (2015).
  MedlineGoogle Scholar
• 79. Chandrasegaram MD, Eslick GD, Lee W et al. Anticoagulation policy after venous resection with a pancreatectomy: a systematic review. HPB (Oxford) 16(8), 691–698 (2014).
  MedlineGoogle Scholar
• 80. Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J. Gastrointest. Surg. 14(9), 1442–1452 (2010).
  MedlineGoogle Scholar
• 81. Tang D, Zhang JQ, Wang DR. Long term results of pancreatectomy with portal-superior mesenteric vein resection for pancreatic carcinoma: a systematic review. Hepatogastroenterology 58(106), 623–631 (2011).
  MedlineGoogle Scholar
• 82. Zhou Y, Zhang Z, Liu Y et al. Pancreatectomy combined with superior mesenteric vein–portal vein resection for pancreatic cancer: a meta-analysis. World J. Surg. 36(4), 884–891 (2012).
  MedlineGoogle Scholar
• 83. Yu XZ, Li J, Fu DL et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur. J. Surg. Oncol. 40(4), 371–378 (2014).
  Medline CASGoogle Scholar
• 84. Giovinazzo F, Turri G, Katz MH et al. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br. J. Surg. 103(3), 179–191 (2016).
  Medline CASGoogle Scholar
• 85. Bell R, Te Ao B, Ironside N et al. Meta-analysis and cost-effective analysis of portal-superior mesenteric vein resection during pancreatoduodenectomy: impact on margin status and survival. Surg. Oncol. 26(1), 53–62 (2017).
  MedlineGoogle Scholar
• 86. Peng C, Zhou D, Meng L et al. The value of combined vein resection in pancreaticoduodenectomy for pancreatic head carcinoma: a meta-analysis. BMC Surg. 19(1), 1–3 (2019).
  MedlineGoogle Scholar
• 87. Fancellu A, Petrucciani N, Porcu A et al. The impact on survival and morbidity of portal–mesenteric resection during pancreaticoduodenectomy for pancreatic head adenocarcinoma: a systematic review and meta-analysis of comparative studies. Cancers 12(7), 1976 (2020). •• Latest meta-anlaysis comparing PD with PD-SVR, which emphasised that though SVR has increased the R0 resection rates, it has not uniformly led to a benefit in survival, thus emphasizing on further research is to evaluate the role of PD with SVR in the context of multimodality treatment of PC.
  CASGoogle Scholar
• 88. Natsume T, Shuto K, Yanagawa N, Akai T, Kawahira H, Hayashi H, Matsubara H. The classification of anatomic variations in the perigastric vessels by dual-phase CT to reduce intraoperative bleeding during laparoscopic gastrectomy. Surg. Endosc. 25(5), 1420–1424 (2011).
  MedlineGoogle Scholar
• 89. Hackert T, Weitz J, Büchler MW. Reinsertion of the gastric coronary vein to avoid venous gastric congestion in pancreatic surgery. HPB (Oxford) 17(4), 368–370 (2015).
  MedlineGoogle Scholar
• 90. Isaji S, Mizuno S, Windsor JA et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18(1), 2–11 (2018).
  MedlineGoogle Scholar
• 91. Liebig C, Ayala G, Wilks JA et al. Perineural invasion in cancer: a review of the literature. Cancer 115(15), 3379–3391 (2009).
  Medline CASGoogle Scholar
• 92. Klompmaker S, De Rooij T, Korteweg JJ et al. Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer. Br. J. Surg. 103(8), 941–949 (2016).
  Medline CASGoogle Scholar
• 93. Gong H, Ma R, Gong J et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer: a systematic review and meta-analysis. Medicine 95(10), e3061 (2016).
  MedlineGoogle Scholar
• 94. Klompmaker S, Peters NA, Van Hilst J et al. Outcomes and risk score for distal pancreatectomy with celiac axis resection (DP-CAR): an international multicenter analysis. Ann. Surg. Oncol. 26(3), 772–781 (2019).
  MedlineGoogle Scholar
• 95. Nimura Y. Our experience of resection of carcinoma of the body and tail of the pancreas by Appleby's procedure. Shujutsu 15, 885–9 (1976).
  Google Scholar
• 96. Okada KI, Kawai M, Tani M et al. Preservation of the left gastric artery on the basis of anatomical features in patients undergoing distal pancreatectomy with celiac axis en-bloc resection (DP-CAR). World J. Surg. 38(11), 2980–2985 (2014).
  MedlineGoogle Scholar
• 97. Aosasa S, Nishikawa M, Noro T et al. Total pancreatectomy with celiac axis resection and hepatic artery restoration using splenic artery autograft interposition. J. Gastrointest. Surg. 20(3), 644–647 (2016).
  MedlineGoogle Scholar
• 98. Okada KI, Hirono S, Kawai M et al. Left gastric artery reconstruction after distal pancreatectomy with celiac axis en-bloc resection: how we do it. Gastrointest. Tumors 4(1–2), 28–35 (2017).
  Medline CASGoogle Scholar
• 99. Ueda A, Sakai N, Yoshitomi H et al. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? World J. Surg. Oncol. 17(1), 124 (2019).
  MedlineGoogle Scholar
• 100. Kimura W, Han I, Furukawa Y et al. Appleby operation for carcinoma of the body and tail of the pancreas. Hepatogastroenterology 44(14), 387–393 (1997).
  Medline CASGoogle Scholar
• 101. Dong Y, Jin JB, Peng CH. Clinical effect of modified Appleby operation in the treatment of carcinoma of body and tail of the pancreas. J. Surg. Concepts. Pract. 18, 142–146 (2013).
  Google Scholar
• 102. Miyakawa S, Horiguchi A, Hanai T et al. Monitoring hepatic venous hemoglobin oxygen saturation during Appleby operation for pancreatic cancer. Hepatogastroenterology 49(45), 817–821 (2002).
  MedlineGoogle Scholar
• 103. Shimura M, Ito M, Horiguchi A et al. Distal pancreatectomy with en bloc celiac axis resection performed while monitoring hepatic arterial flow by using a transonic flowmeter during operation. Hepatogastroenterology 59(117), 1498–1500 (2012).
  MedlineGoogle Scholar
• 104. Nishino H, Takano S, Yoshitomi H et al. Ischemic gastropathy after distal pancreatectomy with en bloc celiac axis resection versus distal pancreatectomy for pancreatic body/tail cancer. Surg. Open. Sci. 1(1), 14–19 (2019).
  MedlineGoogle Scholar
• 105. Nakamura T, Hirano S, Noji T et al. Distal pancreatectomy with en bloc celiac axis resection (modified Appleby procedure) for locally advanced pancreatic body cancer: a single-center review of 80 consecutive patients. Ann. Surg. Oncol. 23(5), 969–975 (2016).
  MedlineGoogle Scholar
• 106. Sato T, Inoue Y, Takahashi Y et al. Distal pancreatectomy with celiac Axis resection combined with reconstruction of the left gastric artery. J. Gastrointest. Surg. 21(5), 910–917 (2017).
  MedlineGoogle Scholar
• 107. Tanaka E, Hirano S, Tsuchikawa T et al. Important technical remarks on distal pancreatectomy with en-bloc celiac axis resection for locally advanced pancreatic body cancer (with video). J. Hepatobiliary Pancreat. Sci. 19(2), 141–147 (2012).
  MedlineGoogle Scholar
• 108. Denecke T, Andreou A, Podrabsky P et al. Distal pancreatectomy with en bloc resection of the celiac trunk for extended pancreatic tumor disease: an interdisciplinary approach. Cardiovasc. Intervent. Radiol. 34(5), 1058–1064 (2011).
  MedlineGoogle Scholar
• 109. Hirano S, Kondo S, Tanaka E et al. Postoperative bowel function and nutritional status following distal pancreatectomy with en-bloc celiac axis resection. Dig. Surg. 27(3), 212–216 (2010).
  MedlineGoogle Scholar
• 110. Takahashi Y, Kaneoka Y, Maeda A et al. Distal pancreatectomy with celiac axis resection for carcinoma of the body and tail of the pancreas. World J. Surg. 35(11), 2535–2542 (2011).
  MedlineGoogle Scholar
• 111. McIntyre CA, Zambirinis CP, Pulvirenti A et al. Detailed analysis of margin positivity and the site of local recurrence after pancreaticoduodenectomy. Ann. Surg. Oncol. 28(1), 539–549 (2021).
  MedlineGoogle Scholar
• 112. Klaiber U, Mihaljevic A, Hackert T. Radical pancreatic cancer surgery—with arterial resection. Transl. Gastroenterol. Hepatol. 4, 8 (2019).
  MedlineGoogle Scholar
• 113. Jegatheeswaran S, Baltatzis M, Jamdar S et al. Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review. HPB (Oxford) 19(6), 483–490 (2017).
  MedlineGoogle Scholar
• 114. Stitzenberg KB, Watson JC, Roberts A et al. Survival after pancreatectomy with major arterial resection and reconstruction. Ann. Surg. Oncol. 15(5), 1399–1406 (2008).
  MedlineGoogle Scholar
• 115. Wang C, Wu H, Xiong J et al. Pancreaticoduodenectomy with vascular resection for local advanced pancreatic head cancer: a single center retrospective study. J. Gastrointest. Surg. 12(12), 2183 (2008).
  MedlineGoogle Scholar
• 116. Yamamoto Y, Sakamoto Y, Ban D et al. Is celiac axis resection justified for T4 pancreatic body cancer? Surgery 151(1), 61–9 (2012).
  MedlineGoogle Scholar
• 117. Yoshidome H, Shimizu H, Ohtsuka M et al. Pancreaticoduodenetomy combined with hepatic artery resection following preoperative hepatic arterial embolization. J. Hepatobiliary Pancreat. Sci. 21(12), 850–855 (2014).
  MedlineGoogle Scholar
• 118. Glebova NO, Hicks CW, Tosoian JJ et al. Outcomes of arterial resection during pancreatectomy for tumor. J. Vasc. Surg. 63(3), 722–729 (2016).
  MedlineGoogle Scholar
• 119. Miyazaki M, Yoshitomi H, Takano S et al. Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer. Langenbeck's Arch. Surg. 402(3), 447–456 (2017).
  MedlineGoogle Scholar
• 120. Loveday BP, Zilbert N, Serrano PE et al. Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas. HPB (Oxford) 21(6), 643–652 (2019).
  MedlineGoogle Scholar
• 121. Tee MC, Krajewski AC, Groeschl RT et al. Indications and perioperative outcomes for pancreatectomy with arterial resection. J. Am. Coll. Surg. 227(2), 255–269 (2018).
  MedlineGoogle Scholar
• 122. Bachellier P, Addeo P, Faitot F et al. Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes: a single institution's experience with 118 patients. Ann. Surg. 271(5), 932–940 (2020).
  MedlineGoogle Scholar
• 123. Mollberg N, Rahbari NN, Koch M et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann. Surg. 254(6), 882–893 (2011).
  MedlineGoogle Scholar
• 124. Małczak P, Sierżęga M, Stefura T et al. Arterial resections in pancreatic cancer: systematic review and meta-analysis. HPB (Oxford) 22(7), 961–968 (2020).
  MedlineGoogle Scholar
• 125. Haines M, Chua TC, Jamieson NB et al. Pancreatoduodenectomy with arterial resection for locally advanced pancreatic cancer of the head: a systematic review. Pancreas 49(5), 621–628 (2020).
  MedlineGoogle Scholar
• 126. Rebelo A, Büdeyri I, Heckler M et al. Systematic review and meta-analysis of contemporary pancreas surgery with arterial resection. Langenbeck's Arch. Surg. 405(7), 903–919 (2020). •• Latest comprehensive meta-analysis on arterial resections in pancreatic cancer.
  MedlineGoogle Scholar
• 127. Sanjay P, Takaori K, Govil S et al. ‘Artery-first’ approaches to pancreatoduodenectomy. Br. J. Surg. 99(8), 1027–1035 (2012).
  Medline CASGoogle Scholar
• 128. Christians KK, Pilgrim CH, Tsai S et al. Arterial resection at the time of pancreatectomy for cancer. Surgery 155(5), 919–926 (2014).
  MedlineGoogle Scholar
• 129. Inoue Y, Saiura A, Yoshioka R et al. Pancreatoduodenectomy with systematic mesopancreas dissection using a supracolic anterior artery-first approach. Ann. Surg. 262(6), 1092–1101 (2015).
  MedlineGoogle Scholar
• 130. Diener MK, Mihaljevic AL, Strobel O et al. Periarterial divestment in pancreatic cancer surgery. Surgery 169(5), 1019–1025 (2021).
  MedlineGoogle Scholar
• 131. Hackert T, Strobel O, Michalski CW et al. The TRIANGLE operation–radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxford) 19(11), 1001–1007 (2017).
  MedlineGoogle Scholar
• 132. Barreto SG, Kleeff J. Synchronous arterial resections in pancreatic cancer–still a matter of debate? Eur. J. Surg. Oncol. 47(2), 480–482 (2021). • Highlights why arterial resections have not translated into improved survival beyond technical feasilbility.
  MedlineGoogle Scholar
• 133. Dresler CM, Fortner JG, Mcdemott KA et al. Metabolic consequences of (regional) total pancreatectomy. Ann. Surg. 214(2), 131–140 (1991).
  Medline CASGoogle Scholar
• 134. Burdelski CM, Reeh M, Bogoevski D et al. Multivisceral resections in pancreatic cancer: identification of risk factors. World J. Surg. 35(12), 2756–2763 (2011).
  MedlineGoogle Scholar
• 135. Hartwig W, Vollmer CM, Fingerhut A et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 156(1), 1–4 (2014).
  MedlineGoogle Scholar
• 136. Malinka T, Klein F, Andreou A et al. Distal pancreatectomy combined with multivisceral resection is associated with postoperative complication rates and survival comparable to those after standard procedures. J. Gastrointest. Surg. 22(9), 1549–1556 (2018).
  MedlineGoogle Scholar
• 137. Adam U, Makowiec F, Riediger H et al. Risk factors for complications after pancreatic head resection. Am. J. Surg. 187(2), 201–208 (2004).
  MedlineGoogle Scholar
• 138. Suzuki Y, Fujino Y, Tanioka Y et al. Resection of the colon simultaneously with pancreaticoduodenectomy for tumors of the pancreas and periampullary region: short-term and long-term results. World J. Surg. 28(10), 1007–1010 (2004).
  MedlineGoogle Scholar
• 139. Muscari F, Suc B, Kirzin S et al. Risk factors for mortality and intra-abdominal complications after pancreatoduodenectomy: multivariate analysis in 300 patients. Surgery 139(5), 591–598 (2006).
  MedlineGoogle Scholar
• 140. Bhayani NH, Enomoto LM, James BC et al. Multivisceral and extended resections during pancreatoduodenectomy increase morbidity and mortality. Surgery 155(3), 567–574 (2014).
  MedlineGoogle Scholar
• 141. Siripong A, Chung M, Rich SE. Multivisceral Pancreatic Resections: Worth the Risk? Clin. Surg. 3, 1869 (2018).
  Google Scholar
• 142. Kleeff J, Diener MK, Z'graggen K et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann. Surg. 245(4), 573–582 (2007).
  MedlineGoogle Scholar
• 143. Irani JL, Ashley SW, Brooks DC et al. Distal pancreatectomy is not associated with increased perioperative morbidity when performed as part of a multivisceral resection. J. Gastrointest. Surg. 12(12), 2177–2182 (2008).
  MedlineGoogle Scholar
• 144. Seeliger H, Christians S, Angele MK et al. Risk factors for surgical complications in distal pancreatectomy. Am. J. Surg. 200(3), 311–317 (2010).
  MedlineGoogle Scholar
• 145. Roch AM, Singh H, Turner AP et al. Extended distal pancreatectomy for pancreatic adenocarcinoma with splenic vein thrombosis and/or adjacent organ invasion. Am. J. Surg. 209(3), 564–569 (2015).
  MedlineGoogle Scholar
• 146. Panzeri F, Marchegiani G, Malleo G et al. Distal pancreatectomy associated with multivisceral resection: results from a single center experience. Langenbeck's Arch. Surg. 402(3), 457–464 (2017).
  MedlineGoogle Scholar
• 147. Sahakyan MA, Kleive D, Kazaryan AM et al. Extended laparoscopic distal pancreatectomy for adenocarcinoma in the body and tail of the pancreas: a single-center experience. Langenbeck's Arch. Surg. 403(8), 941–948 (2018).
  MedlineGoogle Scholar
• 148. Ramia JM, Juan V, Blanco-Fernández G et al. Distal pancreatectomy with multivisceral resection: A retrospective multicenter study–Case series. Int. J. Surg. 82, 123–129 (2020).
  MedlineGoogle Scholar
• 149. Beetz O, Sarisin A, Kaltenborn A et al. Multivisceral resection for adenocarcinoma of the pancreatic body and tail—a retrospective single-center analysis. World J. Surg. Oncol. 18(1), 218 (2020).
  MedlineGoogle Scholar
• 150. Strobel O, Hinz U, Gluth A et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann. Surg. 261(5), 961–969 (2015).
  MedlineGoogle Scholar
• 151. Manabe T, Ohshio G, Baba N et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 64(5), 1132–1137 (1989).
  Medline CASGoogle Scholar
• 152. Ishikawa OS, Ohhigashi HI, Sasaki Y et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann. Surg. 208(2), 215–220 (1988).
  Medline CASGoogle Scholar
• 153. Isaji S, Murata Y, Kishiwada M. New Japanese classification of pancreatic cancer. In: Text book of Pancreatic Cancer. Neoptolemos JP (Ed.). 1–7 (2016).
  Google Scholar
• 154. Tol JA, Gouma DJ, Bassi C et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156(3), 591–600 (2014).
  MedlineGoogle Scholar
• 155. Pedrazzoli S, DiCarlo V, Dionigi R et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann. Surg. 228(4), 508–517 (1998).
  Medline CASGoogle Scholar
• 156. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann. Surg. 236(3), 355–366 (2002).
  MedlineGoogle Scholar
• 157. Nimura Y, Nagino M, Takao S et al. Standard versus extended lymphadenectomy. Long term results of randomized trial. J. Hepatobiliary Pancreat. Sci. 19, 230–241 (2012).
  MedlineGoogle Scholar
• 158. Farnell MB, Pearson RK, Sarr MG et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138(4), 618–630 (2005).
  MedlineGoogle Scholar
• 159. Jang JY, Kang MJ, Heo JS et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann. Surg. 259(4), 656–664 (2014).
  MedlineGoogle Scholar
• 160. Sperling J, Schuld J, Hechler AM et al. Extended versus standard lymphadenectomy in patients undergoing pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective randomized single center trial. Eur. Surg. 48(1), 26–33 (2016).
  Google Scholar
• 161. Ignjatovic I, Knezevic S, Knezevic D et al. Standard versus extended lymphadenectomy in radical surgical treatment for pancreatic head carcinoma. J. BUON. 22(1), 232–238 (2017).
  MedlineGoogle Scholar
• 162. Michalski CW, Kleeff J, Wente MN et al. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br. J. Surg. 94(3), 265–273 (2007).
  Medline CASGoogle Scholar
• 163. Iqbal N, Lovegrove RE, Tilney HS et al. A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy: a meta-analysis of 1909 patients. Eur. J. Surg. Oncol. 35(1), 79–86 (2009).
  Medline CASGoogle Scholar
• 164. Sun J, Yang Y, Wang X et al. Meta-analysis of the efficacies of extended and standard pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas. World J. Surg. 38(10), 2708–2715 (2014).
  MedlineGoogle Scholar
• 165. Yin Z, Ma T, Jin H et al. Too much water drowned the miller: does extended pancreaticoduodenectomy benefit the long-term survival outcomes in the treatment of pancreatic cancer? Ann. Surg. 265(4), e39–41 (2017).
  MedlineGoogle Scholar
• 166. Wang W, He Y, Wu L et al. Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma: an update meta-analysis. Pancreatology 19(8), 1074–1080 (2019).
  MedlineGoogle Scholar
• 167. Staerkle RF, Vuille-dit-Bille RN, Soll C et al. Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. Cochrane Database Syst. Rev. 1(1), CD011490 (2021). •• Latest Cochrane review/meta-analysis of randomized control trials which highlights absence of survival benefit with extended lymphadenectomy.
  MedlineGoogle Scholar
• 168. Pawlik TM, Abdalla EK, Barnett CC et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch. Surg. 140(6), 584–591 (2005).
  MedlineGoogle Scholar
• 169. Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann. Surg. Oncol. 13(9), 1189–1200 (2006).
  MedlineGoogle Scholar
• 170. Huebner M, Kendrick M, Reid-Lombardo KM et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J. Gastrointest. Surg. 16(5), 920–926 (2012).
  MedlineGoogle Scholar
• 171. Farid SG, Falk GA, Joyce D et al. Prognostic value of the lymph node ratio after resection of periampullary carcinomas. HPB (Oxford) 16(6), 582–591 (2014).
  MedlineGoogle Scholar
• 172. Macedo FI, Picado O, Hosein PJ et al. Does neoadjuvant chemotherapy change the role of regional lymphadenectomy in pancreatic cancer survival? Pancreas 48(6), 823–831 (2019).
  MedlineGoogle Scholar
• 173. Slidell MB, Chang DC, Cameron JL et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann. Surg. Oncol. 15(1), 165–174 (2008).
  MedlineGoogle Scholar
• 174. Hellan M, Sun CL, Artinyan A et al. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas 37(1), 19–24 (2008).
  MedlineGoogle Scholar
• 175. Tomlinson JS, Jain S, Bentrem DJ et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch. Surg. 142(8), 767–774 (2007).
  MedlineGoogle Scholar
• 176. Showalter TN, Winter KA, Berger AC et al. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int. J. Radiat. Oncol. Biol. Phys. 81(5), 1328–1335 (2011).
  MedlineGoogle Scholar
• 177. Vuarnesson H, Lupinacci RM, Semoun O et al. Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinoma. Eur. J. Surg. Oncol. 39(10), 1116–1121 (2013).
  Medline CASGoogle Scholar
• 178. Valsangkar NP, Bush DM, Michaelson JS et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J. Gastrointest. Surg. 17(2), 257–266 (2013).
  MedlineGoogle Scholar
• 179. Hua J, Zhang B, Xu J et al. Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: an analysis using the nodal staging score model. Eur. J. Surg. Oncol. 45(6), 1069–1076 (2019).
  MedlineGoogle Scholar
• 180. Malleo G, Maggino L, Qadan M et al. Reassessment of the optimal number of examined lymph nodes in pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Ann. Surg. Nov 9 2020.
  Google Scholar
• 181. Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann. Surg. Oncol. 25(4), 845–847 (2018).
  MedlineGoogle Scholar
• 182. Ashfaq A, Pockaj BA, Gray RJ et al. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J. Gastrointest. Surg. 18(11), 1929–1935 (2014).
  MedlineGoogle Scholar
• 183. Malleo G, Maggino L, Ferrone CR et al. Number of examined lymph nodes and nodal status assessment in distal pancreatectomy for body/tail ductal adenocarcinoma. Ann. Surg. 270(6), 1138–1146 (2019).
  MedlineGoogle Scholar
• 184. Shrikhande SV, Barreto SG, Shukla PJ. Laparoscopy in pancreatic tumors. J. Min. Access. Surg. 3(2), 47–51 (2007).
  Medline CASGoogle Scholar
• 185. Barreto SG. Pancreatic cancer. In: Surgical diseases of the pancreas and biliary tree. Barreto SGWindsor J (Ed.). Springer, Singapore, 427–469 (2018).
  Google Scholar
• 186. Shrikhande SV, Barreto SG, Sirohi B et al. Indian council of medical research consensus document for the management of pancreatic cancer. Indian. J. Med. Paediatr. Oncol. 40(1), 9–14 (2019).
  Google Scholar
• 187. Hariharan D, Constantinides VA, Froeling FE et al. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers:a meta-analysis. Eur. J. Surg. Oncol. 36(10), 941–948 (2010).
  Medline CASGoogle Scholar
• 188. Clements R, Saber A, Teixeira J et al. Guidelines for institutions granting bariatric privileges utilizing laparoscopic techniques. Society of American Gastrointestinal and Endoscopic Surgeons Guidelines Committee. Surg. Endosc. 25(3), 671–676 (2011).
  MedlineGoogle Scholar
• 189. Levy J, Tahiri M, Vanounou T et al. Diagnostic laparoscopy with ultrasound still has a role in the staging of pancreatic cancer: a systematic review of the literature. HPB Surg. 2016, 8092109 (2016).
  MedlineGoogle Scholar
• 190. Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg. Endosc. 8(5), 408–410 (1994).
  Medline CASGoogle Scholar
• 191. Gagner M, Pomp A, Herrera MF. Early experience with laparoscopic resections of islet cell tumors. Surgery 120(6), 1051–1054 (1996).
  Medline CASGoogle Scholar
• 192. Hopkins MP, Dulai RM, Occhino A et al. The effects of carbon dioxide pneumoperitoneum on seeding of tumor in port sites in a rat model. Am. J. Obstet. Gynecol. 181(6), 1329–1334 (1999).
  Medline CASGoogle Scholar
• 193. Shukla PJ, Barreto SG, Shrikhande SV et al. Detection of gall bladder cancer metastases in rare sites by PET scan. Indian J. Gastroenterol. 26(6), 303–304 (2007).
  MedlineGoogle Scholar
• 194. Giulianotti PC, Coratti A, Angelini M et al. Robotics in general surgery: personal experience in a large community hospital. Arch. Surg. 138(7), 777–784 (2003).
  MedlineGoogle Scholar
• 195. Asbun HJ, Moekotte AL, Vissers FL et al. The Miami international evidence-based guidelines on minimally invasive pancreas resection. Ann. Surg. 271(1), 1–4 (2020).
  MedlineGoogle Scholar
• 196. van Hilst J, de Rooij T, Bosscha K et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumors (LEOPARD-2): a multicenter, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol. Hepatol. 4(3), 199–207 (2019). •• Multicenter RCT from the Netherlands, which showed increased complication related mortality in laparoscopic PD in comparison to open PD, and was prematurely terminated, thus urging caution in widespread utilization of minimally invasive PD.
  MedlineGoogle Scholar
• 197. de Rooij T, van Hilst J, van Santvoort H et al. Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann. Surg. 269(1), 2–9 (2019).
  MedlineGoogle Scholar
• 198. Björnsson B, Larsson AL, Hjalmarsson C et al. Comparison of the duration of hospital stay after laparoscopic or open distal pancreatectomy: randomized controlled trial. Br. J. Surg. 107(10), 1281–1288 (2020).
  Medline CASGoogle Scholar
• 199. van Hilst J, Korrel M, de Rooij T et al. Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Eur. J. Surg. Oncol. 45(5), 719–727 (2019).
  MedlineGoogle Scholar
• 200. Yang DJ, Xiong JJ, Lu HM et al. The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Sci. Reports 9(1), 1–8 (2019).
  MedlineGoogle Scholar
• 201. Zhou J, Lv Z, Zou H et al. Up-to-date comparison of robotic-assisted versus open distal pancreatectomy: a PRISMA-compliant meta-analysis. Medicine 99(23), e20345 (2020).
  MedlineGoogle Scholar
• 202. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240(2), 205–213 (2004).
  MedlineGoogle Scholar
• 203. Van Hilst J, Strating EA, De Rooij T et al. Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial). Br. J. Surg. 106(7), 910–921 (2019).
  Medline CASGoogle Scholar
• 204. Joechle K, Conrad C. Cost-effectiveness of minimally invasive pancreatic resection. J. Hepatobiliary Pancreat. Sci. 25, 291–298 (2018).
  MedlineGoogle Scholar
• 205. Gurusamy KS, Riviere D, van Laarhoven CJ et al. Cost-effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer. PLoS ONE. 12(12), e0189631 (2017).
  MedlineGoogle Scholar
• 206. van Hilst J, de Rooij T, Klompmaker S et al. Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study. Ann. Surg. 269(1), 10–17 (2019).
  MedlineGoogle Scholar
• 207. Riviere D, Gurusamy KS, Kooby DA et al. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Cochrane Database Syst. Rev. 4(4), CD011391 (2016).
  MedlineGoogle Scholar
• 208. Anderson KL Jr, Adam MA, Thomas S et al. Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. Am. J. Surg 213(4), 601–605 (2017).
  MedlineGoogle Scholar
• 209. Palanivelu C, Senthilnathan P, Sabnis SC et al. Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumors. Br. J. Surg. 104(11), 1443–1450 (2017).
  Medline CASGoogle Scholar
• 210. Poves I, Burdío F, Morató O et al. Comparison of perioperative outcomes between laparoscopic and open approach for pancreatoduodenectomy: the PADULAP randomized controlled trial. Ann. Surg. 268(5), 731–739 (2018).
  MedlineGoogle Scholar
• 211. Ausania F, Landi F, Martínez-Pérez A et al. A meta-analysis of randomized controlled trials comparing laparoscopic vs open pancreaticoduodenectomy. HPB (Oxford) 21(12), 1613–1620 (2019).
  MedlineGoogle Scholar
• 212. Kang CM, Kim DH, Lee WJ et al. Conventional laparoscopic and robot-assisted spleen-preserving pancreatectomy: does da Vinci have clinical advantages? Surg. Endosc. 25(6), 2004–2009 (2011).
  MedlineGoogle Scholar
• 213. Daouadi M, Zureikat AH, Zenati MS et al. Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann. Surg. 257(1), 128–132 (2013).
  MedlineGoogle Scholar
• 214. Duran H, Ielpo B, Caruso R et al. Does robotic distal pancreatectomy surgery offer similar results as laparoscopic and open approach? A comparative study from a single medical center. Int. J. Med. Robot. 10(3), 280–285 (2014).
  MedlineGoogle Scholar
• 215. Lee SY, Allen PJ, Sadot E et al. Distal pancreatectomy: a single institution's experience in open, laparoscopic, and robotic approaches. J. Am. Coll. Surg. 220(1), 18–27 (2015).
  MedlineGoogle Scholar
• 216. Chen S, Zhan Q, Chen JZ et al. Robotic approach improves spleen-preserving rate and shortens postoperative hospital stay of laparoscopic distal pancreatectomy: a matched cohort study. Surg. Endosc. 29(12), 3507–3518 (2015).
  MedlineGoogle Scholar
• 217. Benizri EI Germain A, Ayav A et al. Short-term perioperative outcomes after robot-assisted and laparoscopic distal pancreatectomy. J. Robot. Surg. 8(2), 125–132 (2014).
  MedlineGoogle Scholar
• 218. Adam MA, Choudhury K, Goffredo P et al. Minimally invasive distal pancreatectomy for cancer: short-term oncologic outcomes in 1733 patients. World J. Surg. 39(10), 2564–2572 (2015).
  MedlineGoogle Scholar
• 219. Eckhardt S, Schicker C, Maurer E et al. Robotic-assisted approach improves vessel preservation in spleen-preserving distal pancreatectomy. Dig. Surg. 33(5), 406–413 (2016).
  MedlineGoogle Scholar
• 220. Goh BK, Chan CY, Soh HL et al. A comparison between robotic-assisted laparoscopic distal pancreatectomy versus laparoscopic distal pancreatectomy. Int. J. Med. Robot. 13(1), e1733 (2017).
  Google Scholar
• 221. Jin JB, Qin K, Li H et al. Robotic enucleation for benign or borderline tumors of the pancreas: a retrospective analysis and comparison from a high-volume center in Asia. World J. Surg. 40(12), 3009–3020 (2016).
  MedlineGoogle Scholar
• 222. Deng Y, Xia A, Zhang S et al. Comparative analysis of clinical short-term outcomes of Da Vinci robot-assisted spleen-preserving distal pancreatectomy and laparoscopic spleen-preserving distal pancreatectomy. Int. J. Surg. 42(9), 596–599 (2015).
  Google Scholar
• 223. Lee KF, Fong A, Chong C et al. Minimally invasive versus open approach for distal pancreatectomy: a retrospective comparative study. HPB (Oxford) 18, e438 (2016).
  Google Scholar
• 224. Waters JA, Canal DF, Wiebke EA et al. Robotic distal pancreatectomy: cost effective? Surgery 148(4), 814–823 (2010).
  MedlineGoogle Scholar
• 225. Butturini G, Damoli I, Crepaz L et al. A prospective non-randomised single-center study comparing laparoscopic and robotic distal pancreatectomy. Surg. Endosc. 29(11), 3163–3170 (2015).
  MedlineGoogle Scholar
• 226. Lai EC, Tang CN. Robotic distal pancreatectomy versus conventional laparoscopic distal pancreatectomy: a comparative study for short-term outcomes. Front. Med. 9(3), 356–360 (2015).
  MedlineGoogle Scholar
• 227. Ryan CE, Ross SB, Sukharamwala PB et al. Distal pancreatectomy and splenectomy: a robotic or LESS approach. JSLS. 19(1), e2014.00246 (2015).
  MedlineGoogle Scholar
• 228. Zhou JY, Xin C, Mou YP et al. Robotic versus laparoscopic distal pancreatectomy: a meta-analysis of short-term outcomes. PLoS One. 11(3), e0151189 (2016).
  MedlineGoogle Scholar
• 229. Gavriilidis P, Lim C, Menahem B et al. Robotic versus laparoscopic distal pancreatectomy: the first meta-analysis. HPB (Oxford) 18(7), 567–574 (2016).
  MedlineGoogle Scholar
• 230. Niu X, Yu B, Yao L et al. Comparison of surgical outcomes of robot-assisted laparoscopic distal pancreatectomy versus laparoscopic and open resections: a systematic review and meta-analysis. Asian J. Surg. 42(1), 32–45 (2019).
  MedlineGoogle Scholar
• 231. Liu R, Zhang T, Zhao ZM et al. The surgical outcomes of robot-assisted laparoscopic pancreaticoduodenectomy versus laparoscopic pancreaticoduodenectomy for periampullary neoplasms: a comparative study of a single center. Surg. Endosc. 31(6), 2380–2386 (2017).
  MedlineGoogle Scholar
• 232. Zhang Y, Hong D, Zhang C et al. Total laparoscopic versus robot-assisted laparoscopic pancreaticoduodenectomy. Biosci. Trends 12(5), 484–490 (2018).
  MedlineGoogle Scholar
• 233. Zimmerman AM, Roye DG, Charpentier KP. A comparison of outcomes between open, laparoscopic and robotic pancreaticoduodenectomy. HPB (Oxford) 20(4), 364–369 (2018).
  MedlineGoogle Scholar
• 234. Nassour I, Wang SC, Porembka MR et al. Robotic versus laparoscopic pancreaticoduodenectomy: a NSQIP analysis. J. Gastrointest. Surg. 21(11), 1784–1792 (2017).
  MedlineGoogle Scholar
• 235. Nassour I, Choti MA, Porembka MR et al. Robotic-assisted versus laparoscopic pancreaticoduodenectomy: oncological outcomes. Surg. Endosc. 32(6), 2907–2913 (2018).
  MedlineGoogle Scholar
• 236. Xourafas D, Pawlik TM, Cloyd JM. Independent predictors of increased operative time and hospital length of stay are consistent across different surgical approaches to pancreatoduodenectomy. J. Gastrointest. Surg. 22(11), 1911–1919 (2018).
  MedlineGoogle Scholar
• 237. Kamarajah SK, Bundred J, Saint Marc O et al. Robotic versus conventional laparoscopic pancreaticoduodenectomy a systematic review and meta-analysis. Eur. J. Surg. Oncol. 46(1), 6–14 (2020).
  MedlineGoogle Scholar
• 238. Pascual M, Alonso S, Parés D et al. Randomized clinical trial comparing inflammatory and angiogenic response after open versus laparoscopic curative resection for colonic cancer. Br. J. Surg. 98(1), 50–59 (2011).
  Medline CASGoogle Scholar
• 239. Okamura A, Takeuchi H, Matsuda S et al. Factors affecting cytokine change after esophagectomy for esophageal cancer. Ann. Surg. Oncol. 22(9), 3130–3135 (2015).
  MedlineGoogle Scholar
• 240. van Hilst J, Brinkman DJ, de Rooij T et al. The inflammatory response after laparoscopic and open pancreatoduodenectomy and the association with complications in a multicenter randomized controlled trial. HPB (Oxford) 21(11), 1453–1461 (2019).
  MedlineGoogle Scholar
• 241. Correa-Gallego C, Dinkelspiel HE, Sulimanoff I et al. Minimally-invasive vs open pancreaticoduodenectomy: systematic review and meta-analysis. J. Am. Coll. Surg. 218(1), 129–139 (2014).
  MedlineGoogle Scholar
• 242. de Rooij T, Lu MZ, Steen MW et al. Minimally invasive versus open pancreatoduodenectomy. Ann. Surg. 264(2), 257–267 (2016).
  MedlineGoogle Scholar
• 243. Pędziwiatr M, Małczak P, Pisarska M et al. Minimally invasive versus open pancreatoduodenectomy—systematic review and meta-analysis. Langenbeck's Arch. Surg. 402(5), 841–851 (2017).
  MedlineGoogle Scholar
• 244. Nickel F, Haney CM, Kowalewski KF et al. Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials. Ann. Surg. 271(1), 54–66 (2020).
  MedlineGoogle Scholar
• 245. Zhang H, Lan X, Peng B et al. Is total laparoscopic pancreaticoduodenectomy superior to open procedure? A meta-analysis. World J. Gastroenterol. 25(37), 5711 (2019).
  MedlineGoogle Scholar